Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Benralizumab for the Prevention of COPD Exacerbations

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Compassionate Use of Remdesivir in Covid-19

    Research output: Contribution to journalLetterResearchpeer-review

  3. Soluble Urokinase Receptor and Acute Kidney Injury

    Research output: Contribution to journalLetterResearchpeer-review

  4. Erythropoietin in Preterm Infants

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Association between Mental Disorders and Subsequent Medical Conditions

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. International severe asthma registry (ISAR): protocol for a global registry

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Airway hyperresponsiveness to mannitol improves in both type 2 high and type 2 low asthma after specialist management

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The six-gene expression signature in whole sampled sputum provides clinically feasible inflammatory phenotyping of asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Fertility Treatment Resulting in Live Births in Women with Asthma - Associated with Perennial Allergy?

    Research output: Contribution to journalJournal articleResearchpeer-review

  • GALATHEA and TERRANOVA Study Investigators
View graph of relations

BACKGROUND: The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.

METHODS: In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on the basis of eosinophil count [≥220 per cubic millimeter vs. <220 per cubic millimeter]) who had frequent exacerbations despite receiving guideline-based inhaled treatment. Patients were randomly assigned to receive benralizumab (30 or 100 mg in GALATHEA; 10, 30, or 100 mg in TERRANOVA) every 8 weeks (every 4 weeks for the first three doses) or placebo. The primary end point was the treatment effect of benralizumab, measured as the annualized COPD exacerbation rate ratio (benralizumab vs. placebo) at week 56 in patients with baseline blood eosinophil counts of 220 per cubic millimeter or greater. Safety was also assessed.

RESULTS: In GALATHEA, the estimates of the annualized exacerbation rate were 1.19 per year (95% confidence interval [CI], 1.04 to 1.36) in the 30-mg benralizumab group, 1.03 per year (95% CI, 0.90 to 1.19) in the 100-mg benralizumab group, and 1.24 per year (95% CI, 1.08 to 1.42) in the placebo group; the rate ratio as compared with placebo was 0.96 for 30 mg of benralizumab (P = 0.65) and 0.83 for 100 mg of benralizumab (P = 0.05). In TERRANOVA, the estimates of the annualized exacerbation rate for 10 mg, 30 mg, and 100 mg of benralizumab and for placebo were 0.99 per year (95% CI, 0.87 to 1.13), 1.21 per year (95% CI, 1.08 to 1.37), 1.09 per year (95% CI, 0.96 to 1.23), and 1.17 per year (95% CI, 1.04 to 1.32), respectively; the corresponding rate ratios were 0.85 (P = 0.06), 1.04 (P = 0.66), and 0.93 (P = 0.40). At 56 weeks, none of the annualized COPD exacerbation rate ratios for any dose of benralizumab as compared with placebo reached significance in either trial. Types and frequencies of adverse events were similar with benralizumab and placebo.

CONCLUSIONS: Add-on benralizumab was not associated with a lower annualized rate of COPD exacerbations than placebo among patients with moderate to very severe COPD, a history of frequent moderate or severe exacerbations, and blood eosinophil counts of 220 per cubic millimeter or greater (Funded by AstraZeneca [GALATHEA and TERRANOVA] and Kyowa Hakko Kirin [GALATHEA]; GALATHEA and TERRANOVA ClinicalTrials.gov numbers, NCT02138916 and NCT02155660.).

Original languageEnglish
JournalThe New England journal of medicine
Pages (from-to)1023-1034
ISSN0028-4793
DOIs
Publication statusPublished - 20 May 2019

ID: 57232235